Sanotize is recruiting for a COVID trial in the province of Quebec.   

NORS2791 product candidate is a topical formulation of NORSTM developed for the treatment of acne, which is a chronic, inflammatory skin condition and among the most common skin disorders seen by physicians.

Acne occurs when pores become clogged by a combination of sebum, an oily substance produced by the skin, dirt and dead skin cells.

Bacteria called Propionibacterium (P.) acnes are often present and may contribute to the redness, swelling and pus accompanying lesions.

Over 90% of individuals worldwide are affected by acne at some point in their life. Approximately 20% of the US population are diagnosed with acne each year, resulting in an estimated $5 billion annual prescription market.

NORSTM acts as an antibacterial but may also inhibit production of pore-clogging cytokines. Specifically, NORSTM has been shown to be highly effective at eradicating  P. acnes,  and SaNOtize’s topical formulation NORS2791 is expected to reduce inflammation and thus acne symptoms.

logged in